Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

DISEASE CHARACTERISTICS: * Histologically confirmed (by open brain biopsy or from a neurosurgical resection of the tumor) supratentorial glioblastoma multiforme (GBM) * WHO grade IV disease * Newly diagnosed disease * Must provide demonstration of an unmethylated MGMT-promoter * At least 2 weeks and no more than 6 weeks since surgery or open biopsy * Tumor tissue specimens (paraffin-embedded and/or frozen) from the GBM surgery or open biopsy must be available for central pathology review, MGMT status determination, and exploratory analysis of PI3-K/Akt/mTOR targets (P70S6K) PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy ≥ 12 weeks * WBC ≥ 3.0 x 10\^9/L * Absolute neutrophil count ≥ 1.5 x10\^9/L * Platelet count ≥ 75.0 x 10\^9/L * Hemoglobin ≥ 10.0 g/dL * Bilirubin ≤ 1.5 times the upper limit of normal (ULN) * Alkaline phosphatase ≤ 2.5 x ULN * AST and/or ALT ≤ 2.5 x ULN * Serum creatinine \< 1.5 x ULN * PT and PTT normal * Negative pregnancy test * Not pregnant or nursing * Fertile patients must use highly effective contraception * No ischemic heart disease in the past 6 months * 12-lead ECG normal * No history of stroke * No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer (with no subsequent evidence of recurrence) * No serious concurrent systemic disorder including any of the following that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol: * Active infection * HIV infection * Cardiac disease * QTc prolongation \> 450/470 msec (males/females) * No patients with a congenital long-QT-syndrome in their own or family medical history, unless eligible at the investigator's discretion * No known hypersensitivity to the study treatment * No known hypersensitivity to antihistamines or other medical reason that prohibits the intake of antihistamines * No current alcohol dependence or drug abuse * No legal incapacity or limited legal capacity * Able to undergo a gadolinium-enhanced MRI of the brain PRIOR CONCURRENT THERAPY: * See Disease Characteristics * At least 4 weeks since prior and no concurrent investigational agent * No prior stereotactic biopsy * At least 30 days since prior drug therapy that has not received regulatory approval for any indication * No chemotherapy within the past 5 years * No prior chemotherapy for a brain tumor * No prior radiotherapy to the head * No other concurrent anticancer therapy * No concurrent anticoagulation therapy except low-dose prophylactic low molecular weight heparin * Concurrent steroid therapy allowed provided patient is on a stable or decreasing dose for ≥ 1 week * At least 14 days since prior and no concurrent enzyme-inducing anticonvulsants (e.g., carbamazepine, phenobarbital, and phenytoin) * No concurrent strong inducers or inhibitors of CYP3A4 * No concurrent planned surgery for other diseases (e.g., dental extraction) * No placement of Gliadel® wafer during prior surgery